MedPath

Effect of curcumin on the prevention of contrast induced nephropathy

Phase 3
Not yet recruiting
Conditions
ephropathy induced by contrast agents.
Nephropathy induced by other drugs, medicaments and biological substances
N14.1
Registration Number
IRCT20210413050958N2
Lead Sponsor
Mashhad University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
227
Inclusion Criteria

All subjects who receive IV. contrast agent (except renal artery angiography candidates)

Exclusion Criteria

Hepatic failure (Child-Pugh Score B or C)
Biliary obstruction
End-stage renal insufficiency (eGFR less than 15 mL/min)
Acute renal insufficiency (BUN/Creatinine more than 20)
A history of reaction to contrast media
Taking potentially nephrotoxic medicines (48 h before and 24 h after the procedure)
Pulmonary oedema
Gastrointestinal disorders (such as diarrhea, vomiting, dehydration, bleeding, malabsorption, indigestion, etc.)
Multiple myeloma
Exposure to contrast media within 7 days before the procedure
Pregnancy
Taking N-acetyl cysteine, teofiline, dopamine, fenoldopam, manitol, and NaHCO3 within 48 h before coronary angiography.

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Increased serum creatinine level. Timepoint: Before the intervention and 48 hours after contrast agent injection. Method of measurement: Creatinine kit.
Secondary Outcome Measures
NameTimeMethod
Blood urea nitrogen. Timepoint: Before the intervention and 48 hours after contrast agent injection. Method of measurement: Blood urea nitrogen kit.;Cell blood count. Timepoint: Before the intervention and 48 hours after contrast agent injection. Method of measurement: Sysmex Cell Counter.;Creatinin. Timepoint: Before the intervention and 48 hours after contrast agent injection. Method of measurement: Serum creatinin kit.
© Copyright 2025. All Rights Reserved by MedPath